Who
Kevin D. Freeman
Director
Company insider
Files Form 4 as: Director, Galectin Therapeutics.
In numbers
- Trades disclosed
- 60
- Buys
- 36
- Sells
- 0
- Bought
- $389K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 2 Jun 2011
- Last trade
- 16 Jan 2026
- Last filed
- 21 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 16 Jan 2026filed 21 Jan 2026 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 23 Dec 2025filed 23 Dec 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $20K5,500 at $3.55 | filing |
| 23 Dec 2025filed 23 Dec 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $20K5,500 at $3.55 | filing |
| 23 Dec 2025filed 23 Dec 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $20K5,500 at $3.55 | filing |
| 17 Jul 2025filed 18 Jul 2025 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $15K5,000 at $2.90 | filing |
| 23 Jan 2025filed 27 Jan 2025 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 24 Dec 2024filed 26 Dec 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,10010,000 at $0.81 | filing |
| 17 Oct 2024filed 17 Oct 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $3,4321,300 at $2.64 | filing |
| 16 Oct 2024filed 16 Oct 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K5,000 at $2.70 | filing |
| 16 Oct 2024filed 16 Oct 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K5,000 at $2.70 | filing |
| 20 Jun 2024filed 20 Jun 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $5,9502,500 at $2.38 | filing |
| 22 Apr 2024filed 22 Apr 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,4502,500 at $2.98 | filing |
| 9 Apr 2024filed 9 Apr 2024 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Code W | —2,063 at $0.00 | filing |
| 24 Jan 2024filed 7 Feb 2024 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 26 Jan 2023filed 30 Jan 2023 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 28 Oct 2022filed 31 Oct 2022 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $14K10,000 at $1.41 | filing |
| 19 May 2022filed 20 May 2022 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $6,6505,000 at $1.33 | filing |
| 18 Apr 2022filed 18 Apr 2022 | GALT Galectin TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,5505,000 at $1.71 | filing |
| 24 Jan 2022filed 25 Jan 2022 | GALT Galectin Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.